Corline Biomedical AB
SSTO:CLBIO13.70
SEK
-0.30
(-2.14%)
ISIN
SE0006887451
Return %
Stock
S&P 500
1Y
-29.92
14.20
3Y
0.74
81.12
5Y
-11.90
68.34
Capital Structure
SEK
•
in mil. unless spec.Working Capital
SEK
•
in mil. unless spec.Growth Rates
SEK
•
in mil. unless spec.Quarterly Revenue
SEK
•
in mil. unless spec.Quarterly Earnings Per Share
SEK
•
in mil. unless spec.Quarterly Dividends Per Share
SEK
•
in mil. unless spec.Company Description
- CEO
- Lars Henrik Nittmar
- Full Time Employees
- 14
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- Lefflersgatan 5 Uppsala UP Sweden 754 50
- IPO Date
- Jun 3, 2015
- Website
- corline.se
- Similar Companies
- Business
- Corline Biomedical AB develops, manufactures, and markets heparin-based solutions aimed at enhancing kidney transplantation, cell therapies, and regenerative medicine applications. Its core product portfolio is based on Corline Heparin Conjugate (CHC) technology, including Renaparin, a treatment for end-stage renal failure; Cytoparin, a cell therapy candidate for type 1 diabetes; and CHC coatings used for medical devices to improve blood compatibility and treat soft tissue injuries. The company also provides antithrombotic and anti-inflammatory surface coating solutions for medical device implants. Founded in 1991, Corline Biomedical is headquartered in Uppsala, Sweden, and primarily operates within the biotechnology and medical device sectors. In recent developments, Corline Biomedical has forged a significant non-exclusive licensing agreement with Canadian medical device company Kardium, granting rights to use its CHS coating technology for Kardium’s Globe ablation catheter, targeting the global market for heart arrhythmia treatment. This partnership is a key strategic move aimed at commercializing the CHS technology in medtech. The company is actively advancing clinical development, although the phase II trial for Renaparin is currently on hold pending financing efforts. Corline is also focusing on building sales momentum through its medtech partnerships, with expectations for improved profitability over the near term supported by FDA approvals and impending product launches. These strategic partnerships and operational focus reflect a transition towards medtech commercialization, positioning Corline for growth in global markets including North America and Europe. Corline Biomedical has approximately 13 employees, and it continues to enhance its product offerings and clinical pipeline within the fields of regenerative medicine and medical device surface coatings. Its recent efforts emphasize strengthening collaborations and securing licensing opportunities to maximize the reach and application of its heparin-based technologies. The company’s positioning targets the evolving demands of the biotechnology and healthcare markets with a focus on improving clinical outcomes in transplantation and device biocompatibility. This comprehensive approach to combining pharmaceutical and medical device coatings with strategic partnerships is central to Corline Biomedical’s current business strategy and reflects the latest changes within the last two years. The company’s developments and partnerships are pivotal as it aims to capitalize on its innovative CHS technology on a global commercial scale.